Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 55Myelodysplastic Syndromes 32Leukemia 18Leukemia, Myelomonocytic, Chronic 11Congenital Abnormalities 5Recurrence 4Neoplasms 4Melanoma 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myeloproliferative Disorders 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Erythroblastic, Acute 3Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Anemia, Refractory, with Excess of Blasts 2Anemia, Refractory 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytopenia 1Thrombocythemia, Essential 1Skin Neoplasms 1Sarcoma, Synovial 1Primary Myelofibrosis 1

Interventions

Paclitaxel 57Carboplatin 51Bevacizumab 41Taxes 28liposomal doxorubicin 21Gemcitabine 19Immunoglobulin G 17Disulfides 17pembrolizumab 15Topotecan 12rucaparib 10Cyclophosphamide 9Cisplatin 9Docetaxel 8olaparib 7Doxorubicin 7pazopanib 6mirvetuximab soravtansine 6cediranib 6Nivolumab 6Magnetic Resonance Spectroscopy 6Specimen Handling 5sargramostim 4niraparib 4Surgical Procedures, Operative 4Drug Therapy 4Cytoreduction Surgical Procedures 4Albumin-Bound Paclitaxel 4veliparib 3fludarabine phosphate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Fallopian Tube Neoplasms × Decitabine × Clear all
NCT02650986 2025-06-17

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Roswell Park Cancer Institute

Phase 1/2 Active not recruiting
15 enrolled 12 charts
DermatologicGynecologicSarcoma

Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡